论文部分内容阅读
为了确定血管扩张药治疗慢性充血性心力衰竭的效果,在804例接受利尿剂与狄戈辛治疗的病人,比较了肼酞嗪-硝异山梨醇和依那普利治疗的效果。采用双盲随机分组方法,两组患者分别接受依那普利(每日20mg)或肼酞嗪(每日300mg)加硝异山梨醇(每日160mg)。二年病死率:依那普利组(18％)低于肼酞嗪-硝异山梨醇组(25％),P=0.016,总死亡率也趋向降低(P=0.08)。依那普利组病死率的降低可归因于猝死发生率的降低,在症状轻的
To determine the efficacy of vasodilators in the treatment of chronic congestive heart failure, the efficacy of hydralazine-isosorbide and enalapril was compared in 804 patients receiving diuretics and diclofenac. Patients were enalapril (20 mg daily) or hydralazine (300 mg daily) plus isosorbide (160 mg daily) in a double-blind randomized study. Two-year mortality was lower in the enalapril group (18%) than in the hydralazine-isosorbide group (P = 0.016) (P = 0.08). The reduction in mortality in the enalapril group was attributable to a decrease in the incidence of sudden death,